查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1716422

2032 年病毒抗原市场预测：按类型、病毒类型、通路、诊断方法、应用、最终用户和地区进行的全球分析

Viral Antigens Market Forecasts to 2032 - Global Analysis By Type, Virus Type, Distribution Channel, Diagnostic Method, Application, End Users and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球病毒抗原市场预计在 2025 年达到 2,354 亿美元，预计到 2032 年将达到 4,646 亿美元，预测期内的复合年增长率为 10.2%。

病毒抗原是源自病毒的分子，可引发人体的免疫反应。这些抗原通常是病毒表面的蛋白质或糖蛋白，被免疫系统识别为外来物质并刺激抗体的产生。病毒抗原在诊断测试、疫苗开发和研究中发挥重要作用。这是因为它可以帮助检测病毒感染、刺激免疫力并了解病毒行为及其与免疫系统的相互作用。

根据美国国家生物技术资讯中心 (NCBI) 的数据，64.44% 的病毒特异性B 细胞表位位于病毒抗原上，这些抗原仍被包裹在病毒颗粒或宿主细胞内。

病毒感染增加

随着世界各地出现新的病毒，对准确诊断和有效抗原治疗的需求日益增加。 COVID-19、肝炎和流感等病毒性疾病凸显了基于抗原的诊断的重要性。通用感染疾病发生率的上升进一步凸显了研究和开发病毒抗原的必要性。此外，技术突破使得人们能够开发出更强大的抗原来对抗病毒感染疾病。总的来说，这些因素导致全球对病毒抗原的需求不断增加。

抗原生产高成本

抗原生产过程涉及重组DNA和单株抗体等昂贵的技术。此外，对专门设施和熟练专业人员的需求也增加了生产成本。品管和安全测试的监管要求进一步增加了製造商的成本。这些成本使得抗原生产对于小公司和开发中国家来说在经济上具有挑战性。这种限制阻碍了病毒抗原在不同地区的广泛可用性和可负担性。

对预防性医疗保健的兴趣日益浓厚

世界各国政府和组织都重视疫苗接种计划，以遏制病毒感染疾病的传播。基于抗原的疫苗在实现预防保健目标中发挥着重要作用。此外，免疫学和抗原技术的进步正在推动疫苗开发的创新。公众对定期检查和接种疫苗等预防措施的认识正在推动市场需求。这一趋势为公司扩大抗原产品组合和满足全球医疗保健需求提供了巨大潜力。

某些病毒抗原的可用性有限

由于病毒结构复杂，有些抗原难以取得或产生。这种限制影响了新发病毒诊断测试和疫苗的及时开发。例如，罕见病毒株或快速变异的病毒可能缺乏适合研究的抗原。此外，供应链中断和地缘政治因素可能会影响某些地区的抗原供应。这些问题威胁到製造商满足日益增长的病毒抗原需求的能力。

COVID-19的影响：

COVID-19 疫情对病毒抗原市场产生了重大影响。基于抗原的病毒诊断检测方法的开发和采用已经加速。对 COVID-19 疫苗的高需求进一步凸显了病毒抗原的重要性。疫情爆发后，人们依然高度重视医疗准备和疫苗研发。这场大流行凸显了病毒抗原在应对全球健康挑战中的作用，推动了市场成长。

预计预测期内，天然抗原部分将占最大份额

由于天然抗原的组成与病毒的结构非常相似并提供精确的免疫反应，因此预计天然抗原部分将在预测期内占据最大的市场占有率。它们在诊断和疫苗开发中的应用对于检测感染和刺激有效免疫至关重要。此外，天然抗原由于其能够产生强大而持久的免疫力而成为疫苗製剂的首选，这增加了其在研究、诊断和治疗应用中的需求。

预计治疗应用领域在预测期内将以最高复合年增长率成长

由于治疗应用领域具有增强免疫疗法和抗病毒治疗的潜力，预计在预测期内将出现最高的成长率。透过刺激有针对性的免疫反应，病毒抗原可能有助于治疗慢性病毒感染和增强人体的防御机制。人们对个人化医疗和病毒性疾病新型治疗方法的日益关注将进一步推动对用于治疗的病毒抗原的需求，以改善患者的治疗效果。

占比最大的地区：

由于肝炎、流感和 COVID-19 等病毒感染疾病的盛行率不断上升，预计亚太地区将在预测期内占据最大的市场占有率。快速的都市化、改善的医疗保健基础设施以及对研究和诊断的不断增加的投资进一步推动了市场的成长。此外，政府努力加强疫苗接种计划和诊断检测，以及提高对病毒性疾病的认识，大大推动了全部区域对病毒抗原的需求。

复合年增长率最高的地区：

由于流感、爱滋病毒和 COVID-19 等病毒感染疾病的盛行率很高，预计欧洲地区在预测期内的复合年增长率最高，增加了对诊断测试和疫苗的需求。先进的医疗基础设施、广泛的生物技术研发以及政府对公共卫生倡议的大力支持促进了市场的成长。此外，对病毒性疾病的认识不断提高以及快速诊断的需求是推动该地区对病毒抗原需求的主要因素。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球病毒抗原市场（按类型）

  • 天然抗原
  • 重组抗原
  • 合成抗原
  • 灭活抗原
  • 减毒活抗原
  • 其他类型

6. 全球病毒抗原市场（依病毒类型）

  • 人类免疫力缺乏病毒（HIV）
  • 流感病毒
  • 肝炎病毒
  • COVID-19（SARS-CoV-2）
  • 单纯疱疹病毒（HSV）
  • 其他病毒类型

7. 全球病毒抗原市场（依通路）

  • 直销
  • 网上销售
  • 第三方经销商
  • 零售药局

8. 全球病毒抗原市场（依诊断方法）

  • 基于抗原的诊断套件
  • 免疫过氧化物酶染色
  • 免疫检测
  • 血凝反应
  • 免疫测量（RIA）
  • 萤光
  • 电子显微镜

9. 全球病毒抗原市场（依应用）

  • 诊断
    • 病毒检测测试
    • 血清学检测
    • 聚合酵素链锁反应反应（PCR）
  • 疫苗研发
  • 研究与开发
  • 治疗用途
  • 其他用途

第 10 章全球病毒抗原市场（依最终用户）

  • 研究和诊断实验室
  • 製药和生物技术公司
  • 医院
  • 学术和政府研究组织
  • 兽医诊所
  • 其他最终用户

第 11 章全球病毒抗原市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • Creative Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Microbix Biosystems Inc.
  • Aalto Bio Reagents
  • Prospec-Tany Technogene Ltd.
  • Sino Biological, Inc.
  • Meridian Bioscience
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific, Inc.
  • Abbott
  • Cepheid
  • The Native Antigen Company
  • DiaSorin SpA
  • Quidel Corporation
  • Randox Laboratories Ltd.
Product Code: SMRC29233

According to Stratistics MRC, the Global Viral Antigens Market is accounted for $235.40 billion in 2025 and is expected to reach $464.60 billion by 2032 growing at a CAGR of 10.2% during the forecast period. Viral antigens are molecules derived from viruses that trigger an immune response in the body. These antigens, typically proteins or glycoproteins found on the surface of the virus, are recognized by the immune system as foreign, prompting the production of antibodies. Viral antigens play a crucial role in diagnostic tests, vaccine development, and research, as they help detect viral infections, stimulate immunity, and contribute to understanding viral behaviors and interactions with the immune system.

According to the National Centre for Biotechnology Information (NCBI), 64.44% virus-specific B cell epitopes are situated in viral antigens that remain enclosed within viral particles or host cells.

Market Dynamics:

Driver:

Increasing prevalence of viral infections

The demand for precise diagnoses and efficient antigen-based treatments is increasing as novel strains appear all over the world. The significance of antigen-based diagnostics has been brought to light by viral illnesses such as COVID-19, hepatitis, and influenza. The need for viral antigen research and development is further highlighted by the rising incidence of zoonotic illnesses. Furthermore, the development of more potent antigens to fight viral outbreaks has been made possible by technological breakthroughs. These factors collectively contribute to the increased demand for viral antigens worldwide.

Restraint:

High costs of antigen production

The manufacturing process for antigens involves expensive technologies like recombinant DNA and monoclonal antibodies. Additionally, the need for specialized facilities and skilled professionals adds to the production cost. Regulatory requirements for quality control and safety testing further increase expenses for manufacturers. Small-scale companies and developing nations face financial challenges in antigen production due to these costs. This limitation hampers widespread accessibility and affordability of viral antigens across various regions.

Opportunity:

Growing focus on preventive healthcare

Governments and organizations worldwide are emphasizing vaccination programs to curb the spread of viral infections. Antigen-based vaccines play a crucial role in achieving preventive healthcare objectives. Moreover, advancements in immunology and antigen technologies are driving innovation in vaccine development. Public awareness about preventive measures, such as regular screening and vaccination, is boosting market demand. This trend creates immense potential for companies to expand their antigen product portfolios and cater to global healthcare needs.

Threat:

Limited Availability of Certain Viral Antigens

Some antigens are difficult to source or produce due to the complexity of viral structures. This limitation affects the timely development of diagnostic tests and vaccines for emerging viruses. For instance, rare viral strains or rapidly mutating viruses may lack suitable antigens for research. Additionally, supply chain disruptions and geopolitical factors can affect antigen availability in certain regions. These issues threaten the ability of manufacturers to meet the growing demand for viral antigens.

Covid-19 Impact:

The COVID-19 pandemic has had a profound impact on the Viral Antigens Market. It accelerated the development and adoption of antigen-based diagnostic tests to detect the virus. The high demand for COVID-19 vaccines further highlighted the importance of viral antigens. Post-pandemic, the focus on healthcare preparedness and vaccine development remains strong. The pandemic emphasized the role of viral antigens in addressing global health challenges and driving market growth.

The native antigens segment is expected to be the largest during the forecast period

The native antigens segment is expected to account for the largest market share during the forecast period, due to their natural composition, which closely mimics the structure of the virus, providing accurate immune responses. Their use in diagnostics and vaccine development is crucial for detecting infections and stimulating effective immunity. Additionally, native antigens are preferred in vaccine formulations for their ability to produce robust and long-lasting immunity, increasing demand across research, diagnostics, and therapeutic applications.

The therapeutic use segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the therapeutic use segment is predicted to witness the highest growth rate, driven by their potential to enhance immunotherapies and antiviral treatments. By stimulating targeted immune responses, viral antigens can aid in treating chronic viral infections or boosting the body's defense mechanisms. The increasing focus on personalized medicine and the development of novel treatments for viral diseases further propels the demand for viral antigens in therapeutic applications, improving patient outcomes.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to the increasing prevalence of viral infections, such as hepatitis, influenza, and COVID-19. Rapid urbanization, improving healthcare infrastructure, and growing investments in research and diagnostics are further fueling market growth. Additionally, government initiatives promoting vaccination programs and diagnostic testing, along with the rising awareness of viral diseases, are significantly boosting the demand for viral antigens across the region.

Region with highest CAGR:

Over the forecast period, the Europe region is anticipated to exhibit the highest CAGR, owing to the high prevalence of viral infections, including influenza, HIV, and COVID-19, which increases the demand for diagnostic tests and vaccines. Advanced healthcare infrastructure, extensive research and development in biotechnology, and strong government support for public health initiatives contribute to market growth. Furthermore, rising awareness of viral diseases and the need for rapid diagnostics are key factors driving demand for viral antigens in the region.

Key players in the market

Some of the key players in Viral Antigens Market include Creative Diagnostics, Bio-Rad Laboratories, Inc., Microbix Biosystems Inc., Aalto Bio Reagents, Prospec-Tany Technogene Ltd., Sino Biological, Inc., Meridian Bioscience, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Abbott, Cepheid, The Native Antigen Company, DiaSorin S.p.A, Quidel Corporation, and Randox Laboratories Ltd.

Key Developments:

In February 2025, Shedd Aquarium and global healthcare company Abbott are announcing one of Shedd's largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

In November 2024, Microbix Biosystems Inc. announces that key opinion leader ("KOL") collaborators are presenting results of a Microbix Quality Assessment Product ("QAP(TM)") for controlling testing for high-risk types of Human Papilloma Virus ("HPV") at the 36th annual International Papillomavirus Conference ("IPVC") taking place in Edinburgh, Scotland.

Types Covered:

  • Native Antigens
  • Recombinant Antigens
  • Synthetic Antigens
  • Inactivated Antigen
  • Live Attenuated Antigens
  • Other Types

Virus Types Covered:

  • Human Immunodeficiency Virus (HIV)
  • Influenza Virus
  • Hepatitis Virus
  • COVID-19 (SARS-CoV-2)
  • Herpes Simplex Virus (HSV)
  • Other Virus Types

Distribution Channels Covered:

  • Direct Sales
  • Online Sales
  • Third-Party Distributors
  • Retail Pharmacies

Diagnostic Methods Covered:

  • Antigen-based Diagnostic Kits
  • Immunoperoxidase Staining
  • Immunoassays
  • Hemagglutination
  • Radioimmunoassay (RIA)
  • Immunofluorescence
  • Electron Microscopy

Applications Covered:

  • Diagnostics
  • Vaccine Development
  • Research and Development
  • Therapeutic Use
  • Other Applications

End Users Covered:

  • Research and Diagnostic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Hospitals
  • Academic and Government Research Institutes
  • Veterinary Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Antigens Market, By Type

  • 5.1 Introduction
  • 5.2 Native Antigens
  • 5.3 Recombinant Antigens
  • 5.4 Synthetic Antigens
  • 5.5 Inactivated Antigen
  • 5.6 Live Attenuated Antigens
  • 5.7 Other Types

6 Global Viral Antigens Market, By Virus Type

  • 6.1 Introduction
  • 6.2 Human Immunodeficiency Virus (HIV)
  • 6.3 Influenza Virus
  • 6.4 Hepatitis Virus
  • 6.5 COVID-19 (SARS-CoV-2)
  • 6.6 Herpes Simplex Virus (HSV)
  • 6.7 Other Virus Types

7 Global Viral Antigens Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Direct Sales
  • 7.3 Online Sales
  • 7.4 Third-Party Distributors
  • 7.5 Retail Pharmacies

8 Global Viral Antigens Market, By Diagnostic Method

  • 8.1 Introduction
  • 8.2 Antigen-based Diagnostic Kits
  • 8.3 Immunoperoxidase Staining
  • 8.4 Immunoassays
  • 8.5 Hemagglutination
  • 8.6 Radioimmunoassay (RIA)
  • 8.7 Immunofluorescence
  • 8.8 Electron Microscopy

9 Global Viral Antigens Market, By Application

  • 9.1 Introduction
  • 9.2 Diagnostics
    • 9.2.1 Viral Detection Tests
    • 9.2.2 Serology Tests
    • 9.2.3 Polymerase Chain Reaction Assays (PCR)
  • 9.3 Vaccine Development
  • 9.4 Research and Development
  • 9.5 Therapeutic Use
  • 9.6 Other Applications

10 Global Viral Antigens Market, By End User

  • 10.1 Introduction
  • 10.2 Research and Diagnostic Laboratories
  • 10.3 Pharmaceutical and Biotechnology Companies
  • 10.4 Hospitals
  • 10.5 Academic and Government Research Institutes
  • 10.6 Veterinary Clinics
  • 10.7 Other End Users

11 Global Viral Antigens Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Creative Diagnostics
  • 13.2 Bio-Rad Laboratories, Inc.
  • 13.3 Microbix Biosystems Inc.
  • 13.4 Aalto Bio Reagents
  • 13.5 Prospec-Tany Technogene Ltd.
  • 13.6 Sino Biological, Inc.
  • 13.7 Meridian Bioscience
  • 13.8 F. Hoffmann-La Roche Ltd
  • 13.9 Thermo Fisher Scientific, Inc.
  • 13.10 Abbott
  • 13.11 Cepheid
  • 13.12 The Native Antigen Company
  • 13.13 DiaSorin S.p.A
  • 13.14 Quidel Corporation
  • 13.15 Randox Laboratories Ltd.

List of Tables

  • Table 1 Global Viral Antigens Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Viral Antigens Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Viral Antigens Market Outlook, By Native Antigens (2024-2032) ($MN)
  • Table 4 Global Viral Antigens Market Outlook, By Recombinant Antigens (2024-2032) ($MN)
  • Table 5 Global Viral Antigens Market Outlook, By Synthetic Antigens (2024-2032) ($MN)
  • Table 6 Global Viral Antigens Market Outlook, By Inactivated Antigen (2024-2032) ($MN)
  • Table 7 Global Viral Antigens Market Outlook, By Live Attenuated Antigens (2024-2032) ($MN)
  • Table 8 Global Viral Antigens Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 9 Global Viral Antigens Market Outlook, By Virus Type (2024-2032) ($MN)
  • Table 10 Global Viral Antigens Market Outlook, By Human Immunodeficiency Virus (HIV) (2024-2032) ($MN)
  • Table 11 Global Viral Antigens Market Outlook, By Influenza Virus (2024-2032) ($MN)
  • Table 12 Global Viral Antigens Market Outlook, By Hepatitis Virus (2024-2032) ($MN)
  • Table 13 Global Viral Antigens Market Outlook, By COVID-19 (SARS-CoV-2) (2024-2032) ($MN)
  • Table 14 Global Viral Antigens Market Outlook, By Herpes Simplex Virus (HSV) (2024-2032) ($MN)
  • Table 15 Global Viral Antigens Market Outlook, By Other Virus Types (2024-2032) ($MN)
  • Table 16 Global Viral Antigens Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 17 Global Viral Antigens Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 18 Global Viral Antigens Market Outlook, By Online Sales (2024-2032) ($MN)
  • Table 19 Global Viral Antigens Market Outlook, By Third-Party Distributors (2024-2032) ($MN)
  • Table 20 Global Viral Antigens Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 21 Global Viral Antigens Market Outlook, By Diagnostic Method (2024-2032) ($MN)
  • Table 22 Global Viral Antigens Market Outlook, By Antigen-based Diagnostic Kits (2024-2032) ($MN)
  • Table 23 Global Viral Antigens Market Outlook, By Immunoperoxidase Staining (2024-2032) ($MN)
  • Table 24 Global Viral Antigens Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 25 Global Viral Antigens Market Outlook, By Hemagglutination (2024-2032) ($MN)
  • Table 26 Global Viral Antigens Market Outlook, By Radioimmunoassay (RIA) (2024-2032) ($MN)
  • Table 27 Global Viral Antigens Market Outlook, By Immunofluorescence (2024-2032) ($MN)
  • Table 28 Global Viral Antigens Market Outlook, By Electron Microscopy (2024-2032) ($MN)
  • Table 29 Global Viral Antigens Market Outlook, By Application (2024-2032) ($MN)
  • Table 30 Global Viral Antigens Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 31 Global Viral Antigens Market Outlook, By Viral Detection Tests (2024-2032) ($MN)
  • Table 32 Global Viral Antigens Market Outlook, By Serology Tests (2024-2032) ($MN)
  • Table 33 Global Viral Antigens Market Outlook, By Polymerase Chain Reaction Assays (PCR) (2024-2032) ($MN)
  • Table 34 Global Viral Antigens Market Outlook, By Vaccine Development (2024-2032) ($MN)
  • Table 35 Global Viral Antigens Market Outlook, By Research and Development (2024-2032) ($MN)
  • Table 36 Global Viral Antigens Market Outlook, By Therapeutic Use (2024-2032) ($MN)
  • Table 37 Global Viral Antigens Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 38 Global Viral Antigens Market Outlook, By End User (2024-2032) ($MN)
  • Table 39 Global Viral Antigens Market Outlook, By Research and Diagnostic Laboratories (2024-2032) ($MN)
  • Table 40 Global Viral Antigens Market Outlook, By Pharmaceutical and Biotechnology Companies (2024-2032) ($MN)
  • Table 41 Global Viral Antigens Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 42 Global Viral Antigens Market Outlook, By Academic and Government Research Institutes (2024-2032) ($MN)
  • Table 43 Global Viral Antigens Market Outlook, By Veterinary Clinics (2024-2032) ($MN)
  • Table 44 Global Viral Antigens Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.